The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study
Open accessAbstract
BACKGROUND: This double-blind, multicenter, placebo-controlled study determined the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR) and maintaining SR for 1 year. METHODS AND RESULTS: Patients with AF or AFl (n=325) were randomized to 125, 250, or 500 microgram dofetilide or placebo twice daily. Dosages were adjusted for QTc response and, after 105 patients were enrolled, for calculated creatinine clearance (Cl(Cr)). Pharmacological cardioversion rates for 125, 250, and 500 microgram dofetilide were 6.1%, 9.8%, and 29.9%, respectively, versus 1.2% for placebo (250 and 500 microgram versus placebo; P=0.015 and P<0.001, respectively). Seventy percent of pharmacological cardioversions with dofetilide were achieved in 24 hours and 91% in 36 hours. For the 250 patients who successfully cardioverted pharmacologically or electrically, the probability of remaining in SR at 1 year was 0.40, 0.37, 0.58 for 125, 250, and 500 microgram dofetilide, respectively, and 0.25 for placebo (500 microgram versus placebo, P=0.001). Two cases of torsade de pointes occurred, 1 on day 2 and the other on day 3 (0.8% of all patients given active drug); 1 sudden cardiac death, classified as proarrhythmic, occurred on day 8 (0.4% of all patients given active drug). CONCLUSIONS: Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardioverting AF or AFl to SR and significantly effective in maintaining SR for 1 year. In-hospital initiation and dosage adjustment based on QTc and Cl(Cr) are necessary to minimize a small but nonnegligible proarrhythmic risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dofetilide and ibutilide, pure class III AADs, are very effective for interrupting AFL in intravenous administration, while Class Ia and Ic drugs have little or no effect.138 -142,149”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [149]
In the citing paper
“Dofetilide is moderately effective in cardioverting AF or AFL to SR, and significantly effective in maintaining SR but in-hospital initiation and dosage adjustment based on QTc and renal function are necessary to minimize a small but not negligible proarrhythmic risk.149”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Julian, D. G., CAMM, A. J., Frangin, G., Janse, M. J., Munoz, A., Pj, S., & Simon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09145-3 · Cited by 1,100
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
Torp-Pedersen, C. T., Møller, M., Bloch-Thomsen, P.-E., Køber, L., Sandøe, E., Egstrup, K., Agner, E., Carlsen, J. E., Videbæk, J., Marchant, B., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411201 · Cited by 1,012
Cairns, J. A., Connolly, S. J., Roberts, R. E., & Gent, M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08171-8 · Cited by 949
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 946
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
Flaker, G. C., Blackshear, J. L., McBride, R., Kronmal, R. A., Halperin, J. L., & Hart, R. G. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90003-6 · Cited by 633
Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide.
Carmeliet, E. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10827-6 · Cited by 322
Bubien, R. S., Knotts-Dolson, S. M., Plumb, V. J., & Kay, G. N. (1996) · Circulation · doi:10.1161/01.cir.94.7.1585 · Cited by 284
Disch, D. L., Greenberg, M. L., Holzberger, P. T., Malenka, D. J., & Birkmeyer, J. D. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-6-199403150-00001 · Cited by 86
Coz, F. L., Funck‐Brentano, C., Morell, T., Ghadanfar, M. M., & Jaillon, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90038-1 · Cited by 63
Sedgwick, M. L., Rasmussen, H. S., & Cobbe, S. M. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90996-c · Cited by 63
Cited by
Sorted by citations
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A. M., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 3,072
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Metadata
- Authors
- Singh, S., Zoble, R. G., Yellen, L., Brodsky, M. A., Feld, G. K., Berk, M., & Billing, C. B.
- Affiliations
- United States Department of Veterans Affairs (US)
- Pfizer (United States) (US)
- Venue
- Circulation
- Published
- 2000-11-07
- Volume
- 102
- Issue
- 19
- Pages
- 2385-2390
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2047496300
- Cited by
- 433
- References
- 14
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 12 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 14 · 2019: 10 · 2018: 15 · 2017: 21 · 2016: 26 · 2015: 23 · 2014: 21 · 2013: 15 · 2012: 13
- FWCI
- 21.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- dofetilide, atrial fibrillation, atrial flutter, sinus rhythm maintenance, pharmacological cardioversion, class III antiarrhythmic agents, proarrhythmic risk, torsades de pointes, sudden cardiac death, QTc monitoring, creatinine clearance, dose adjustment
- MeSH terms
- Administration, Oral, Adult, Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Double-Blind Method, Drug Administration Schedule, Female, Heart Rate, Humans, Male, Middle Aged, Phenethylamines, Placebos, Sulfonamides, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
